Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase
- PMID: 2105156
Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase
Abstract
Oxidative metabolism of the polyfunctional alkylating agent N,N',N''-triethylenethiophosphoramide (thio-TEPA) was studied in isolated rat liver microsomes and purified, reconstituted cytochrome P-450 (P-450) enzyme systems in order to elucidate the pathways of drug oxidation and to identify the possible contributions of individual P-450 enzymes to the bioactivation of this chemotherapeutic agent. Rat liver microsomes were found to catalyze conversion of thio-TEPA to its oxo metabolite, N,N',N''-triethylenephosphoramide (TEPA), in a P-450-dependent reaction that was markedly stimulated by prior in vivo treatment with drug inducers of hepatic P-450 subfamily IIB (phenobarbital), but not by pretreatment with inducers of P-450 subfamilies IA (beta-naphthoflavone) or IIE (isoniazid). Thio-TEPA depletion and TEPA formation catalyzed by phenobarbital-induced liver microsomes were both inhibited by greater than 90% by antibodies selectively reactive with P-450 PB-4 (gene product IIB1), the major phenobarbital-inducible rat liver microsomal P-450 form, but not by antibodies inhibitory toward 7 other rat hepatic P-450s. Oxidation of thio-TEPA to TEPA was also catalyzed by purified P-450 PB-4 (Km (app) 19 microM; Vmax (app) = 11 mol thio-TEPA metabolized/min/mol P-450 PB-4) following reconstitution of the cytochrome with NADPH P-450 reductase in a lipid environment. Metabolism of thio-TEPA by P-450 PB-4 was associated with a suicide inactivation of the cytochrome characterized by kinactivation = 0.096 min-1, KI = 24 microM, and a partition ratio of 136 +/- 28 (SD) mol thio-TEPA metabolized/mol P-450 inactivated. The thio-TEPA metabolite TEPA, however, did not inactivate the cytochrome, nor was it subject to further detectable metabolism. In microsomal incubations, metabolism of thio-TEPA led to the inactivation of P-450 PB-4 (steroid 16 beta-hydroxylase) as well as P-450 IIIA-related enzymes (steroid 6 beta-hydroxylase) and the P-450-independent enzyme steroid 17 beta-hydroxysteroid:NADP+ 17-oxidoreductase, as demonstrated by use of the P-450 form-selective steroidal substrate androst-4-ene-3,17-dione. In contrast, little or no inactivation of microsomal P-450 IIA-related enzymes (steroid 7 alpha-hydroxylase) or microsomal NADPH P-450 reductase was observed.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.Cancer Res. 1991 May 1;51(9):2340-5. Cancer Res. 1991. PMID: 1707751
-
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA.Cancer Res. 1991 Aug 15;51(16):4360-6. Cancer Res. 1991. PMID: 1714342
-
Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics.Mol Pharmacol. 1989 May;35(5):736-43. Mol Pharmacol. 1989. PMID: 2725477
-
Drug control of steroid metabolism by the hepatic endoplasmic reticulum.Drug Metab Rev. 1983;14(6):1119-44. doi: 10.3109/03602538308991424. Drug Metab Rev. 1983. PMID: 6373207 Review.
-
Regulatory mechanisms in the activation of nitrogenous compounds by mammalian cytochrome P-450 isozymes.Drug Metab Rev. 1994;26(1-2):325-48. doi: 10.3109/03602539409029801. Drug Metab Rev. 1994. PMID: 8082573 Review.
Cited by
-
First-principles studies on two-dimensional B3O3 adsorbent as a potential drug delivery platform for TEPA anticancer drug.J Mol Model. 2021 Nov 8;27(12):347. doi: 10.1007/s00894-021-04930-x. J Mol Model. 2021. PMID: 34748097
-
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.Br J Clin Pharmacol. 2001 Jan;51(1):61-70. doi: 10.1046/j.1365-2125.2001.01301.x. Br J Clin Pharmacol. 2001. PMID: 11167666 Free PMC article.
-
A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics.Biochem Pharmacol. 2011 Apr 15;81(8):1043-53. doi: 10.1016/j.bcp.2011.01.024. Epub 2011 Feb 12. Biochem Pharmacol. 2011. PMID: 21300029 Free PMC article.
-
Dosing of thioTEPA for myeloablative therapy.Cancer Chemother Pharmacol. 1995;37(1-2):155-60. Cancer Chemother Pharmacol. 1995. PMID: 7497586 Clinical Trial.
-
Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.Cancer Chemother Pharmacol. 1991;28(6):441-7. doi: 10.1007/BF00685820. Cancer Chemother Pharmacol. 1991. PMID: 1718615
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous